1263 related articles for article (PubMed ID: 25537519)
1. Classification of current anticancer immunotherapies.
Galluzzi L; Vacchelli E; Bravo-San Pedro JM; Buqué A; Senovilla L; Baracco EE; Bloy N; Castoldi F; Abastado JP; Agostinis P; Apte RN; Aranda F; Ayyoub M; Beckhove P; Blay JY; Bracci L; Caignard A; Castelli C; Cavallo F; Celis E; Cerundolo V; Clayton A; Colombo MP; Coussens L; Dhodapkar MV; Eggermont AM; Fearon DT; Fridman WH; Fučíková J; Gabrilovich DI; Galon J; Garg A; Ghiringhelli F; Giaccone G; Gilboa E; Gnjatic S; Hoos A; Hosmalin A; Jäger D; Kalinski P; Kärre K; Kepp O; Kiessling R; Kirkwood JM; Klein E; Knuth A; Lewis CE; Liblau R; Lotze MT; Lugli E; Mach JP; Mattei F; Mavilio D; Melero I; Melief CJ; Mittendorf EA; Moretta L; Odunsi A; Okada H; Palucka AK; Peter ME; Pienta KJ; Porgador A; Prendergast GC; Rabinovich GA; Restifo NP; Rizvi N; Sautès-Fridman C; Schreiber H; Seliger B; Shiku H; Silva-Santos B; Smyth MJ; Speiser DE; Spisek R; Srivastava PK; Talmadge JE; Tartour E; Van Der Burg SH; Van Den Eynde BJ; Vile R; Wagner H; Weber JS; Whiteside TL; Wolchok JD; Zitvogel L; Zou W; Kroemer G
Oncotarget; 2014 Dec; 5(24):12472-508. PubMed ID: 25537519
[TBL] [Abstract][Full Text] [Related]
2. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the immune system to improve cancer therapy.
Papaioannou NE; Beniata OV; Vitsos P; Tsitsilonis O; Samara P
Ann Transl Med; 2016 Jul; 4(14):261. PubMed ID: 27563648
[TBL] [Abstract][Full Text] [Related]
4. New anticancer immunotherapies.
Franks HA; Wang Q; Patel PM
Anticancer Res; 2012 Jul; 32(7):2439-53. PubMed ID: 22753700
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy: sipuleucel-T and beyond.
Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
[TBL] [Abstract][Full Text] [Related]
6. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
7. Delivering safer immunotherapies for cancer.
Milling L; Zhang Y; Irvine DJ
Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
[TBL] [Abstract][Full Text] [Related]
8. Folate-targeted immunotherapies: Passive and active strategies for cancer.
Farran B; Pavitra E; Kasa P; Peela S; Rama Raju GS; Nagaraju GP
Cytokine Growth Factor Rev; 2019 Feb; 45():45-52. PubMed ID: 30770191
[TBL] [Abstract][Full Text] [Related]
9. Self-Assembly as a Molecular Strategy to Improve Immunotherapy.
Froimchuk E; Carey ST; Edwards C; Jewell CM
Acc Chem Res; 2020 Nov; 53(11):2534-2545. PubMed ID: 33074649
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of cancer.
Borghaei H; Smith MR; Campbell KS
Eur J Pharmacol; 2009 Dec; 625(1-3):41-54. PubMed ID: 19837059
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapies, their safety and toxicity.
Alatrash G; Jakher H; Stafford PD; Mittendorf EA
Expert Opin Drug Saf; 2013 Sep; 12(5):631-45. PubMed ID: 23668362
[TBL] [Abstract][Full Text] [Related]
12. Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.
Bonavida B; Chouaib S
Ann Oncol; 2017 Mar; 28(3):457-467. PubMed ID: 27864216
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines.
García-Fernández C; Saz A; Fornaguera C; Borrós S
Cancer Gene Ther; 2021 Sep; 28(9):935-946. PubMed ID: 33837365
[TBL] [Abstract][Full Text] [Related]
14. Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy.
Michelle Xu M; Pu Y; Weichselbaum RR; Fu YX
Oncogene; 2017 Feb; 36(5):585-592. PubMed ID: 27425593
[TBL] [Abstract][Full Text] [Related]
15. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy comes of age.
Topalian SL; Weiner GJ; Pardoll DM
J Clin Oncol; 2011 Dec; 29(36):4828-36. PubMed ID: 22042955
[TBL] [Abstract][Full Text] [Related]
17. Advances in immunotherapy delivery from implantable and injectable biomaterials.
Leach DG; Young S; Hartgerink JD
Acta Biomater; 2019 Apr; 88():15-31. PubMed ID: 30771535
[TBL] [Abstract][Full Text] [Related]
18. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh L; Ladoire S; Coukos G; Ghiringhelli F
Ann Oncol; 2015 Sep; 26(9):1813-1823. PubMed ID: 25922066
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
20. Highlights into historical and current immune interventions for cancer.
Cole K; Al-Kadhimi Z; Talmadge JE
Int Immunopharmacol; 2023 Apr; 117():109882. PubMed ID: 36848790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
